Updated Review on Clinically-Relevant Properties of Delafloxacin - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Antibiotics Année : 2023

Updated Review on Clinically-Relevant Properties of Delafloxacin

Résumé

The extensive use of fluoroquinolones has been consequently accompanied by the emergence of bacterial resistance, which triggers the necessity to discover new compounds. Delafloxacin is a brand-new anionic non-zwitterionic fluoroquinolone with some structural particularities that give it attractive proprieties: high activity under acidic conditions, greater in vitro activity against Gram-positive bacteria-even those showing resistance to currently-used fluoroquinolones-and nearly equivalent affinity for both type-II topoisomerases (i.e., DNA gyrase and topoisomerase IV). During phases II and III clinical trials, delafloxacin showed non-inferiority compared to standard-of-care therapy in the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, which resulted in its approval in 2017 by the Food and Drug Administration for indications. Thanks to its overall good tolerance, its broad-spectrum in vitro activity, and its ease of use, it could represent a promising molecule for the treatment of bacterial infections.
Fichier principal
Vignette du fichier
antibiotics-12-01241.pdf (1.74 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04200476 , version 1 (08-09-2023)

Licence

Paternité

Identifiants

Citer

Adrien Turban, François Guérin, Aurelien Dinh, Vincent Cattoir. Updated Review on Clinically-Relevant Properties of Delafloxacin. Antibiotics, 2023, 12 (8), pp.1241. ⟨10.3390/antibiotics12081241⟩. ⟨hal-04200476⟩
12 Consultations
10 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More